These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38266402)

  • 21. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
    Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
    J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p/UCHL3/AhR axis.
    Xu LM; Yuan YJ; Yu H; Wang S; Wang P
    J Transl Med; 2022 Aug; 20(1):350. PubMed ID: 35918714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Prognostic Risk Model Based on Oxidative StressRelated Genes for Platinum-Resistant Ovarian Cancer Patients.
    Su H; Hou Y; Zhu D; Pang R; Tian S; Ding R; Chen Y; Zhang S
    Recent Pat Anticancer Drug Discov; 2024 May; ():. PubMed ID: 38756073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UCHL3 promotes hepatocellular carcinoma progression by stabilizing EEF1A1 through deubiquitination.
    Zhao J; Huo Q; Zhang J; Sun K; Guo J; Cheng F; Hu X; Xu Q
    Biol Direct; 2024 Jul; 19(1):53. PubMed ID: 38965582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
    Xu F; Liu T; Zhou Z; Zou C; Xu S
    Front Immunol; 2021; 12():749369. PubMed ID: 34745121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the KRT7 Biomarker in Immune Infiltration and Paclitaxel Resistance in Ovarian.
    Wang S; Li H; Li M; Liu X; Yu S; Huang H; Wang X
    Altern Ther Health Med; 2023 Jul; 29(5):132-140. PubMed ID: 37023314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer.
    Zhu K; Ma J; Tian Y; Liu Q; Zhang J
    BMC Womens Health; 2024 Jan; 24(1):49. PubMed ID: 38238671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.
    Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L
    Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
    Qiu PY; Deng XH; Li L
    Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
    Cao T; Shen H
    J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The deubiquitinating enzyme UCHL3 promotes anaplastic thyroid cancer progression and metastasis through Hippo signaling pathway.
    Tang J; Yang Q; Mao C; Xiao D; Liu S; Xiao L; Zhou L; Wu G; Tao Y
    Cell Death Differ; 2023 May; 30(5):1247-1259. PubMed ID: 36813921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer.
    Zhang W; Liu T; Jiang L; Chen J; Li Q; Wang J
    Front Genet; 2022; 13():1001239. PubMed ID: 36425071
    [No Abstract]   [Full Text] [Related]  

  • 36. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor.
    Ouyang L; Yan B; Liu Y; Mao C; Wang M; Liu N; Wang Z; Liu S; Shi Y; Chen L; Wang X; Cheng Y; Cao Y; Xiao D; Zhang L; Liu S; Tao Y
    Signal Transduct Target Ther; 2020 Jun; 5(1):78. PubMed ID: 32546741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. UCHL3 promotes aerobic glycolysis of pancreatic cancer through upregulating LDHA expression.
    Fan Y; Hu D; Li D; Ma C; Tang Y; Tao Q; Deng L; Tang D
    Clin Transl Oncol; 2021 Aug; 23(8):1637-1645. PubMed ID: 33616859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.
    Chen S; Wu Y; Wang S; Wu J; Wu X; Zheng Z
    J Ovarian Res; 2022 Mar; 15(1):39. PubMed ID: 35361267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive profiling of endocrine metabolism identifies a novel signature with robust predictive value in ovarian cancer.
    Yu D; Luo Y; Guo R; Ma F; Chang Y; Dang J
    J Gene Med; 2024 May; 26(5):e3686. PubMed ID: 38689382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.